These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6103230)

  • 1. Effect of naloxone on hyperphagia in Prader-Willi syndrome.
    Kyriakides M; Silverstone T; Jeffcoate W; Laurance B
    Lancet; 1980 Apr; 1(8173):876-7. PubMed ID: 6103230
    [No Abstract]   [Full Text] [Related]  

  • 2. [The probable anorexigenic effect of naloxone in the Prader-Labhart-Willi syndrome].
    Mascherpa G; Cogliati F; Mauri R; Resentini M
    Minerva Pediatr; 1982 Aug 15-31; 34(15-16):675. PubMed ID: 7121431
    [No Abstract]   [Full Text] [Related]  

  • 3. Characteristics of abnormal food-intake patterns in children with Prader-Willi syndrome and study of effects of naloxone.
    Zipf WB; Berntson GG
    Am J Clin Nutr; 1987 Aug; 46(2):277-81. PubMed ID: 3618531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
    Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
    PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naloxone and Prader-Willi syndrome.
    Sullivan SN
    Lancet; 1980 May; 1(8178):1140. PubMed ID: 6103478
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
    McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
    Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naloxone and Prader-Willi syndrome.
    McCloy RF; McCloy J
    Lancet; 1980 Jun; 1(8183):1418. PubMed ID: 6104204
    [No Abstract]   [Full Text] [Related]  

  • 8. Topiramate effectiveness in Prader-Willi syndrome.
    Smathers SA; Wilson JG; Nigro MA
    Pediatr Neurol; 2003 Feb; 28(2):130-3. PubMed ID: 12699864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
    Kuppens RJ; Donze SH; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacogenetic aspects of Prader-Willi syndrome.
    Tu JB; Hartridge C; Izawa J
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1137-40. PubMed ID: 1429418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prader-Willi Syndrome, Management of Impulsivity, and Hyperphagia in an Adolescent.
    Puri MR; Sahl R; Ogden S; Malik S
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):403-4. PubMed ID: 27028699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mazindol in two patients with Prader-Willi syndrome.
    Itoh M; Koeda T; Ohno K; Takeshita K
    Pediatr Neurol; 1995 Nov; 13(4):349-51. PubMed ID: 8771175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.
    De Waele K; Ishkanian SL; Bogarin R; Miranda CA; Ghatei MA; Bloom SR; Pacaud D; Chanoine JP
    Eur J Endocrinol; 2008 Oct; 159(4):381-8. PubMed ID: 18603572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of naltrexone, an oral beta-endorphin antagonist, in children with the Prader-Willi syndrome.
    Zlotkin SH; Fettes IM; Stallings VA
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1229-32. PubMed ID: 2944913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prader-Willi syndrome: From genetics to behaviour, with special focus on appetite treatments.
    Griggs JL; Sinnayah P; Mathai ML
    Neurosci Biobehav Rev; 2015 Dec; 59():155-72. PubMed ID: 26475993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.
    Selikowitz M; Sunman J; Pendergast A; Wright S
    Arch Dis Child; 1990 Jan; 65(1):112-4. PubMed ID: 2405783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome.
    Tan TM; Vanderpump M; Khoo B; Patterson M; Ghatei MA; Goldstone AP
    J Clin Endocrinol Metab; 2004 Aug; 89(8):4162-5. PubMed ID: 15292365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
    Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
    J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood.
    Thomson AK
    Dev Med Child Neurol; 2010 Jun; 52(6):506-7. PubMed ID: 19863636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.